‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer

Por Pallis, A G, Voutsina, A, Kalikaki, Ar, Souglakos, J, Briasoulis, E, Murray, S, Koutsopoulos, A, Tripaki, M, Stathopoulos, E, Mavroudis, D, Georgoulias, V
Publicado em 2007

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

Por Souglakos, J, Boukovinas, I, Taron, M, Mendez, P, Mavroudis, D, Tripaki, M, Hatzidaki, D, Koutsopoulos, A, Stathopoulos, E, Georgoulias, V, Rosell, R
Publicado em 2008